Showing papers in "Annals of Oncology in 2005"

TL;DR: Estimates of the cancer burden in Europe in 2004 are presented, including data for the (25 Member States) European Union, to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer.

TL;DR: The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer, reaffirming that the first consideration was endocrine responsiveness.

TL;DR: It is imperative that health professionals explore the use of CAM with their cancer patients, educate them about potentially beneficial therapies in light of the limited available evidence of effectiveness, and work towards an integrated model of health-care provision.

TL;DR: In a substantial proportion of patients, stable disease and even increase in tumor size may be associated with pathologic response to imatinib therapy, and available survival data indicate that the survival of these patients is similar to that of patients with conventional tumor response.

TL;DR: HER-2/neu amplification is common in the intestinal type of gastric carcinoma, and it is associated with a poor outcome, and this hypothesis deserves to be investigated in clinical trials.

TL;DR: Evidence suggests that rapamycin derivatives could induce G1-S cell cycle delay and eventually apoptosis depending on inner cellular characteristics of tumour cells, and strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rap Amycin-resistant tumours.

TL;DR: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases, and a strong correlation was found between response rates and the resection rate.

TL;DR: The broad spectrum of cutaneous side-effects of EGFR inhibitors is outlined, possible underlying mechanisms are discussed and practical guidelines for the management are provided based on literature data and on personal experience.

TL;DR: It was found that the majority of the published research has been conducted in the early stage cancer setting providing mostly descriptive evidence, and there is little evidence of the best method of communicating prognosis or of the impact of prognostic information on patient outcomes.

TL;DR: 2004 consensus statements on the management of ovarian cancer : final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC).

TL;DR: EGFR was overexpressed in this CRC patient population and was significantly associated with TNM (tumor-node-metastasis) stage T3, which suggests this expression-stage association may play a crucial role in a decision to initiate an adjuvant treatment.

TL;DR: An early assessment of chemotherapy response with FDG-PET could provide the basis for selection of patients for alternative therapeutic strategies and be an accurate and independent predictor of PFS and OS.

TL;DR: SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer and a history of bone metastases and Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of S REs occur between scheduled outcome assessments.

TL;DR: Early interimFDG-PET is an accurate and independent predictor of PFS and OS in HL and a positive interim FDG- PET is highly predictive of relapse in advanced-stage disease.

TL;DR: Pemetrexed plus gemcitabine therapy did not improve overall survival in patients with advanced pancreatic cancer, and single-agent gem citabine remains the standard of care for advanced Pancreatic cancer.

TL;DR: CGA could predict STox and overall survival of elderly advanced ovarian carcinoma patients and independent prognostic factors identified for overall survival (Cox model) were depression, FIGO stage IV and more than six different comedications per day.

TL;DR: The present paper critically reviews the current knowledge about the following markers: thymidine labeling index, S phase fraction/flow cytometry, Ki 67, Thymidine kinase (TK), cyclins E, cyclin D, the cyclin inhibitors p27 and p21, and topoisomerase IIalpha.

TL;DR: Once-daily oral dosing of ZD6474 at 300 mg/day is generally well tolerated in patients with advanced solid tumors, and this dose is being investigated in phase II trials.

TL;DR: PCs of both genders had significantly more anxiety than norm samples, and health care personnel in contact with PCs should consider screening them for mental symptoms and QOL and, if necessary, recommend further evaluation by their doctors.

TL;DR: Results indicate that further clinical investigation of BAY 43--9006 is warranted, and suggest it could be a promising future therapy for patients with cancer.

TL;DR: These findings demonstrate that OA, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu overexpression, which, in turn, interacts synergistically with anti-Her-2-neu immunotherapy by promoting apoptotic cell death of breast cancer cells with Her- 2/neU oncogene amplification.

TL;DR: The single cycle of high-dose salvage chemotherapy after three cycles of standard dose chemotherapy had no effect on treatment outcomes, and results suggest that data from uncontrolled studies should not be used to justify routine use of a toxic and expensive treatment without confirmation in a randomised trial.

TL;DR: The apparent high prevalence of T-cell andNK-cell lymphomas in the Chinese was due to more frequent NK-cell but not T- cell lymphomas, which were comparable to Western patients.

TL;DR: EG FR TK mutational analysis is a novel predictive test for selecting lung adenocarcinoma patients for targeted therapy with EGFR TK inhibitors.

TL;DR: Age <35 years and response to first-line chemotherapy predict for improved survival with advanced disease, and synovial sarcoma is a chemosensitive soft tissue sarcomo, compared with historical controls.

TL;DR: CVCs may cause complications in up to 40% of patients, with type of CVC, underlying disease and patient age being the three main factors that affect the incidence of C VC-related complications.

TL;DR: Using microarray techniques, myeloma patients may be subdivided into molecular subgroups with certain clinical characteristics, such as propensity for lytic lesions that may need early prophylactic treatment with bisphosphonates, and phase I studies with recombinant OPG and monoclonal antibodies to RANKL appear promising.

TL;DR: Early response to TAC can reliably identify patients with a high chance of achieving a pathologic complete response (pCR) and new effective treatments need to be explored for patients without an early response.

TL;DR: Tumor resection, the absence of liver and lymph node metastases, and the presence of MEN 1 syndrome are related to a better survival rate and radical surgery continues to have a central role in the therapeutic approach to endocrine tumors of the pancreas.

TL;DR: AsCT constitutes a therapeutic option for HL patients after a first relapse and promising results are observed in patients with low tumour burden at diagnosis, autografted after a long CR and without detectable disease at ASCT.